Analysis of the correlation between levels of cytokines and the clinical active severity in patients with Graves ophthalmopathy

doi:10.3969/j.issn.1006-7795.2023.03.008

Abstract

Abstract: Objective To explore the correlation between plasma levels of 12 cytokines and the clinical activity of the disease in patients with Graves' ophthalmopathy (GO) in active and inactive phases. Methods A total of 27 patients with GO were enrolled, who were diagnosed in the Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University from January 2021 to January 2023. According to their Clinical Activity Score (CAS), the patients were divided into active phase group (14 cases, CAS ≥ 3) and inactive phase group (13 cases, CAS<3) The levels of 12 cytokines in plasma were measured by multiple microsphere flow immunofluorescence luminescence method, including interleukin (IL)-1β IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17, IL-12P70, interferon (IFN)-α, IFN-γ, and tumor necrosis factor (TNF)-α. The clinical characteristics such as gender, age, liver and kidney function, thyroid function, and antibody of all the subjects were collected. Results The levels of IL-1, IL-4, IL-5, IL-8, IL-10, IL-17, IFN-γ and TNF-α in active GO patients were significantly higher than those in inactive GO patients. Levels of TNF-α and IFN-γ were significantly increased in active GO patients, with statistically significant difference (P<0.05). Spearman correlation analysis showed that IL-1, IL-4, IL-5, IL-8, IL-10, IL-17, TNF-α and IFN-γ were significantly positively correlated with CAS score （P< 0.05）. The univariate logistic regression showed that the elevated levels of IL-1, IL-4, IL-5 and IL-17 increase the risk of active phase. Conclusion The levels of IL-1, IL-4, IL-5, IL-8, IL-10 and IL-17 in active GO patients are significantly higher than those in inactive patients, suggesting that these cytokines may participate in the immune response of the disease. Elevated levels of IL-1, IL-4, IL-5 and IL-17 increase the risk of active phase, indicating a potential of these four cytokines as indicators for judging the activity of GO disease.

Key words: Graves' ophthalmopathy, active phase, inactive phase, cytokines, interleukin, clinical activity scoreGraves

CLC Number:

Xie Rongrong, Shi Tingting, Xin Zhong, Cao Xi, Yang Jinkui. Analysis of the correlation between levels of cytokines and the clinical active severity in patients with Graves ophthalmopathy[J]. Journal of Capital Medical University, 2023, 44(3): 407-412.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.03.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I3/407

References

［1］Subekti I, Soewondo P, Soebardi S, et al. Practical guidelines management of Graves ophthalmopathy［J］. Acta Med Indones, 2019, 51(4): 364－371.
［2］Antonelli A, Fallahi P, Elia G, et al. Graves disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy ［J］. Best Pract Res Clin Endocrinol Metab, 2020, 34(1):101388.
［3］Mishra S, Maurya V K, Kumar S, et al. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives［J］. Curr Eye Res, 2020, 45(11):1325－1341.
［4］Fallahi P, Ferrari S M, Elia G, et al. Cytokines as targets of novel therapies for Graves ophthalmopathy［J］. Front Endocrinol (Lausanne),2021, 12:654473.
［5］Jiang M, Zhao J, Wang P, et al. Research progress in Th17 cells and the relevant cytokines in Graves ophthalmopathy［J］. J Central South Univ (Med Ed), 2022, 47(12):1748－1753.
［6］Huang Y, Wu Y, Zhang S, et al. Immunophenotype of lacrimal glands in Graves orbitopathy: implications for the pathogenesis of Th1 and Th17 immunity［J］. Thyroid, 2022,32(8):949－961.
［7］Wang N, Chen F E, Long Z W. Mechanism of microRNA-146a/Notch2 signaling regulating IL-6 in Graves ophthalmopathy［J］. Cell Physiol Biochem, 2017,41(4):1285－1297.
［8］Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves orbitopathy: national multicenter observational study of 48 patients［J］. J Clin Med,2020, 9(9):2816.
［9］Chen Q. The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients［J］. J Cell Biochem, 2019, 120(4):6299－6303.
［10］Du J, Wang X, Tan G, et al. Predisposition to Graves disease and Graves ophthalmopathy by genetic variants of IL2RA［J］. J Mol Med, 2021, 99(10):1487－1495.
［11］Wu T, Mester T, Gupta S, et al. Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy［J］. Thyroid, 2016, 26(12):1768－1777.
［12］Fernando R, Caldera O, Smith T J. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy ［J］. Proc Natl Acad Sci U S A, 2021, 118(52):e2114244118.
［13］Gonnella D. The Th1 chemokine MIG in Graves ophthalmopathy［J］. Clin Ter, 2019, 170(5):e368-e372.
［14］Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy［J］. Sci Rep, 2018, 8(1):10792.
［15］Song R H, Wang B, Yao Q M, et al. Proteomics screening of differentially expressed cytokines in tears of patients with Graves ophthalmopathy［J］. Endocr Metab Immune Disord Drug Targets, 2020, 20(1):87－95.
［16］Fang S, Huang Y, Wang N, et al. Insights into local orbital immunity: evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy［J］. J Clin Endocrinol Metab,2019, 104(5):1697－1711.
［17］Fang S, Lu Y, Huang Y, et al. Mechanisms that underly T cell immunity in Graves orbitopathy［J］. Front Endocrinol (Lausanne), 2021, 12:648732.
［18］Shan J, Jin H, Xu Y. T cell metabolism: a new perspective on Th17/Treg cell imbalance in systemic lupus erythematosus［J］. Front Immunol, 2020, 11:1027.
［19］Dong W, Zhu P. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics［J］. Autoimmun Rev, 2012, 11(12):844－851.
［20］Kociuszko M, Popawska-Kita A, Pawowski P, et al. Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves orbitopathy: a preliminary study［J］. Adv Med Sci, 2021,66(2):315－320.
［21］Mu P W, Tang X X, Wang Y N, et al. Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: A single center prospective randomized trial［J］. Exp Ther Med, 2020,20(6):153.

[1]	Feng Xiaotong, Ke Jing, Zhu Lin, Zhao Dong. Progress in the pathophysiology of diabetes retinopathy [J]. Journal of Capital Medical University, 2023, 44(3): 420-423.
[2]	Liu Chang, Guo Moning, Yuan Yingchao, Zheng Jianpeng, Yang Jinkui . Gender differences and the prediction of type 1 diabetes incidence rate in Beijing from 2013 to 2018 [J]. Journal of Capital Medical University, 2023, 44(3): 370-374.
[3]	Li Yuyang, Zhu Xiaorong, Liu Jing, Zheng Xiaomin, Yang Jinkui, Yang Fangyuan. Analysis of haptoglobin gene polymorphisms and serum haptoglobin levels in patients with diabetes kidney disease [J]. Journal of Capital Medical University, 2023, 44(3): 375-380.
[4]	Li Xiaohui, Yin Jie, Liu Bing, Yu Hengchi, Zhu Yingna, Ma Chifa, Yuan Mingxia. Effect of triglyceride-glucose index in evaluating adipose tissue insulin resistance [J]. Journal of Capital Medical University, 2023, 44(3): 393-399.
[5]	Zheng Xiaomin, Li Bin, Liu Cuiping, Zhou Yingsheng, Cui Limei. Analysis and treatment of dawn phenomenon in elderly patients with type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2023, 44(3): 400-406.
[6]	Li Mingjia, Zhao Miaomiao , Yang Jinkui . Research progress of cathepsin in the mechanism of diabetes and diabetic nephropathy [J]. Journal of Capital Medical University, 2023, 44(3): 413-419.
[7]	Su Zhiyan, Liu Wei, Shi Tingting. Correlation of serum uric acid level and metabolic syndrom in elder patients with type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2023, 44(1): 137-142.
[8]	Guo Yuehong, Huang Jingwei, Chang Yuting, Yang Minfu. Value of ^{99 m}Tc-MIBI SPECT planar imaging and tomographic imaging in diagnosis of primary hyperparathyroidism [J]. Journal of Capital Medical University, 2022, 43(6): 873-879.
[9]	Wang Hua, Shi Tingting, Xin Zhong, Hua Lin, Li Cong, Cao Qiumei. Correlation study between thyrotropin receptor antibodies (TRAb) and intestinal flora and short-chain fatty acids in patients with Graves disease [J]. Journal of Capital Medical University, 2022, 43(6): 931-939.
[10]	An Yu, Bian Nannan, Ding Xiaoyu, Chang Xiaona, Liu Jia, Wang Guang. Dysregulated microbial metabolites in brain of mice with type 1 diabetes mellitus-induced cognitive impairment [J]. Journal of Capital Medical University, 2022, 43(4): 622-629.
[11]	Xiu Shuangling, Fu Junling, Mu Zhijing, Sun Lina, Zhao Lei. Effect of body fat percentage on muscle strength and physical performance in the elders with type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2022, 43(4): 641-646.
[12]	Song Limin, Li Siyuan, Li Jun, Zhao Huirong, Li Jiajia, Wang Shuang. Relationship between polymorphism and mutation of LRP5 and SOST gene with bone metabolism in postmenopausal type 2 diabetic mellitus women in Shihezi,Xinjiang [J]. Journal of Capital Medical University, 2022, 43(2): 269-274.
[13]	Xiu Shuangling, Sun Lina, Mu Zhijing, Fu Junling, Zhao Lei. Comparison of the correlation between muscle mass corrected by different methods and physical function in older adults with type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2022, 43(2): 284-288.
[14]	Yao Shuyang, Li Xiaoxue, Wang Chunxiu, Zhang Yi. Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study [J]. Journal of Capital Medical University, 2022, 43(2): 289-293.
[15]	Xiong Fengran, Lu Jing, Zhang Yingchao, Xie Rongrong, Zhao Ruxuan, Li Qi, Yang Jinkui. Establishment of Kcnh6 gene site-specific mutant mice modeled on a pedigree with monogenic diabetes and the phenotype analysis [J]. Journal of Capital Medical University, 2021, 42(4): 575-581.